GZGang Zhao

Gang Zhao

*This is an algorithmically generated author record based on publicly available information.

Gang Zhao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fluorinated Ultralong-Acting Neuromuscular Blocking Agent with Improved Activity Profile and Biosafety for the Development of Blockade and Reversal Partner Drugs

    by Shi-Xian Gan, Ru-Lei Zhang, Congying Guo, Qiao-Yan Qi, Ke Feng, Shang-Bo Yu, Hui Wang, Wei Zhou, Gang Zhao, Dan-Wei Zhang, et al.

    Halogenation has been used as a useful strategy to optimize an imidazolium-based macrocyclic ultralong-acting neuromuscular blocking agent for improved bioactivity and biocompatibility. A structure–activity relationship study for 18 compounds reveals that monofluorinated macrocycle IMC-X5 displays blockade profiles generally superior to those of lead compound IMC-0. In vivo tests with a rat model show that, compared with those of IMC-0, the onset, profound blockade, and moderate blockade-to-spontaneous respiration times of IMC-X5 at the same dose of 0.2 mg/kg shortens by 47%, extends by 34%, and shortens by 89%, respectively, while the onset activity surpasses that of cisatracurium, one of the main neuromuscular blocking agents, of a clinically associated dose. Moreover, the profound blockade of IMC-X5 can be rapidly reversed by a biocompatible acyclic cucurbit[n]uril (ACB) antagonist at any stage of blockade. IMC-X5 also exhibits a biosafety superior to that of IMC-0. The two agents thus form a promising partnership featuring ultralong-acting blockade and on-demand reversal.

  • Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants

    by Shi-Xian Gan, Yajie Zhu, Congying Guo, Jiangshan Zhang, Haodong Fang, Haofeng Zhu, Ru-Lei Zhang, Xiaoyun Dong, Qiao-Yan Qi, Hui Wang, et al.

    The development of a biocompatible antidote that can efficiently neutralize the anticoagulation activity of both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) represents an unmet medical need. Here, we report that a piperazine-derived tetracationic macrocycle can efficiently neutralize both UFH and LMWHs, including dalteparin, enoxaparin, and nadroparin. In vitro and in vivo assays reveal that the compound outperforms protamine, exhibiting significantly improved neutralization activity, a broad therapeutic window for all heparins, and high biocompatibility, which is confirmed by its very low coagulation and hemolysis effect, as well as a high therapeutic index (20.5), defined as the ratio of the maximum tolerated dose to the effective therapeutic dose. Molecular dynamics simulations indicate that binding may occur through interlocked threading and direct contact patterns, which are stabilized by intermolecular hydrogen bonding and ion-pair electrostatic attraction.